终末期肾病患者冠脉搭桥中动脉移植的生存获益
基于美国肾脏数据系统2015-2021年数据,比较终末期肾病患者接受LIMA+SVG、单纯SVG或多支动脉移植的生存差异。MAG较LIMA无显著生存优势。
要点
- 未移植的ESRD患者中,LIMA较单纯SVG有早期5年生存获益。
- LIMA与单纯SVG的生存差异在4年后逐渐减弱。
- 无论是否移植,MAG较LIMA均无显著5年生存优势。
核心结论
- 未接受移植的ESRD患者中,LIMA移植较单纯SVG有早期生存获益,但4年后差异减弱。
- 无论后续是否移植,MAG较LIMA均未显示显著5年生存优势。
研究设计与样本
- 基于美国肾脏数据系统的回顾性队列研究,纳入2015至2021年所有孤立CABG的ESRD患者。
- 共纳入14917例(89.8%)LIMA、512例(3.1%)MAG和1187例(7.1%)单纯SVG患者,采用IPTW调整基线差异。
临床怎么用
- 对未计划移植的ESRD患者行CABG时,LIMA移植可带来早期生存获益。
- ESRD患者中不应期待MAG较LIMA带来额外生存获益。
局限性
- MAG组样本量较小(512例),可能限制统计效能。
- 研究为回顾性设计,尽管采用IPTW调整,仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: End-stage renal disease (ESRD) is associated with increased morbidity and mortality in patients undergoing coronary artery bypass grafting (CABG); however, the survival benefit of arterial grafting in this population remains unclear. Given the dramatic impact that transplantation can have on long-term survival in patients with ESRD, this study compared hospital and long-term survival for arterial graft vs saphenous vein graft (SVG) only in patients with ESRD who did or did not undergo transplantation. METHODS: With use of the United States Renal Data System, data were collected on all isolated CABG patients along with subsequent transplant status from 2015 to 2021. CABG patterns were divided as left internal mammary artery (LIMA) plus SVG, SVG only, and multiarterial grafting (MAG). Inverse probability of treatment weighting (IPTW) was used to adjust for baseline differences. RESULTS: In total, there were 14,917 (89.8%) patients in LIMA, 512 (3.1%) patients in MAG, and 1187 (7.1%) patients in SVG only. After IPTW, comparison groups were well balanced. In IPTW-adjusted cohorts, LIMA showed a 5-year survival benefit compared with SVG only in patients not receiving transplants (31.6% vs 26.6%; P < .001); however, in landmark analysis, this difference diminished after 4 years. MAG grafting did not show a 5-year survival benefit over LIMA in either patients who did not undergo transplantation (31.7% vs 31.6%; P = .21) or patients who received transplants (80.5% vs 84.8%; P = .65). CONCLUSION: Despite diminished life expectancy for patients with ESRD, there remains an early survival benefit for LIMA grafting in patients who do not undergo transplantation. Limited data did not demonstrate a significant survival benefit for MAG vs LIMA in patients with ESRD regardless of subsequent transplantation status.
引用
- Yang C, Singh S, Ogami T, et al. Arterial Grafting Survival Benefit in Patients With End-Stage Renal Disease Undergoing Coronary Artery Bypass Grafting. Ann Thorac Surg. 2025. PMID: 40907638. doi:10.1016/j.athoracsur.2025.07.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。